Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
1,536 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02613819 | Focal Ablative STereotactic Radiosurgery for Cancers of the Kidney(FASTRACK II) | completed | Phase 2 | 71 | Trans Tasman Radiation Oncology GroupOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT05128825 | A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer(DENALI) | recruiting | Phase 2 | 310 | K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc |
| 8 |
| Sep 29, 2026 |
| clinicaltrials |
| NCT05691478 | A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma | suspended | Phase 2 / Phase 3 | 1,122 | National Cancer Institute (NCI)NIH | 4 | Sep 29, 2026 | clinicaltrials |
| NCT05886920 | A Phase 1/2 Study of D3S-002 as Monotherapy or Combination Therapy in Adult Subjects With Advanced Solid Tumors With MAPK Pathway Mutations | recruiting | Phase 1 / Phase 2 | 67 | D3 Bio (Wuxi) Co., LtdINDUSTRY | 4 | Sep 29, 2026 | clinicaltrials |
| NCT06055075 | A Study Evaluating Safety, Tolerability, and Clinical Activity of Forimtamig-Based Treatment Combinations in Participants With Relapsed or Refractory Multiple Myeloma | terminated | Phase 1 / Phase 2 | 21 | Hoffmann-La RocheINDUSTRY | 6 | Sep 29, 2026 | clinicaltrials |
| NCT06581432 | Beamion PANTUMOR-1: A Study to Test Whether Zongertinib Helps People With Advanced Cancers With HER2 Alterations | recruiting | Phase 2 | 588 | Boehringer IngelheimINDUSTRY | 16 | Sep 29, 2026 | clinicaltrials |
| NCT06619509 | A Study to Test Long-term Treatment With Brigimadlin in People With Solid Tumours Who Took Part in a Previous Study With This Medicine | active not recruiting | Phase 2 | 90 | Boehringer IngelheimINDUSTRY | 20 | Sep 29, 2026 | clinicaltrials |
| NCT06943755 | Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors(STELLAR-311) | recruiting | Phase 2 / Phase 3 | 440 | ExelixisINDUSTRY | 17 | Sep 29, 2026 | clinicaltrials |
| NCT06995677 | Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer(SURF302) | recruiting | Phase 2 | 90 | Tyra Biosciences, IncINDUSTRY | 4 | Sep 29, 2026 | clinicaltrials |
| NCT07190300 | TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)(TulmiSTAR-02) | recruiting | Phase 1 / Phase 2 | 181 | Novartis PharmaceuticalsINDUSTRY | 14 | Sep 29, 2026 | clinicaltrials |
| NCT07226986 | A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC | recruiting | Phase 1 / Phase 2 | 123 | Novartis PharmaceuticalsINDUSTRY | 7 | Sep 29, 2026 | clinicaltrials |
| NCT07659795 | A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer(TARGET-D 203) | recruiting | Phase 2 | 150 | Verastem, Inc.INDUSTRY | 2 | Sep 29, 2026 | clinicaltrials |
| NCT07707895 | DAREON®-36: A Study to Test Obrixtamig in Combination With ZL-1310 in People With Advanced Small Cell Lung Cancer or Other Neuroendocrine Cancers | not yet recruiting | Phase 1 / Phase 2 | 60 | Boehringer IngelheimINDUSTRY | 11 | Sep 29, 2026 | clinicaltrials |
| NCT04973605 | A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma | recruiting | Phase 1 / Phase 2 | 246 | BeOne MedicinesINDUSTRY | 13 | Sep 28, 2026 | clinicaltrials |
| NCT05006716 | A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies(CaDAnCe-101) | recruiting | Phase 1 / Phase 2 | 645 | BeOne MedicinesINDUSTRY | 16 | Sep 28, 2026 | clinicaltrials |
| NCT05327530 | A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma (JAVELIN Bladder Medley) | active not recruiting | Phase 2 | 256 | EMD Serono Research & Development Institute, Inc.INDUSTRY | 12 | Sep 28, 2026 | clinicaltrials |
| NCT05421663 | A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma | active not recruiting | Phase 1 / Phase 2 | 166 | Janssen Research & Development, LLCINDUSTRY | 8 | Sep 28, 2026 | clinicaltrials |
| NCT05562830 | A Substudy of Investigational Agents in Programmed Cell Death-1/Ligand 1 (PD-1/L1) Refractory Locally Advanced or Metastatic Urothelial Carcinoma (mUC) (MK-3475-04A) | recruiting | Phase 1 / Phase 2 | 48 | Merck Sharp & Dohme LLCINDUSTRY | 11 | Sep 28, 2026 | clinicaltrials |
| NCT05867251 | Study of AVZO-021 in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 430 | Avenzo Therapeutics, Inc.INDUSTRY | 2 | Sep 28, 2026 | clinicaltrials |
| NCT06392386 | A Study of Efgartigimod PH20 SC in Children Between 2 and Less Than 18 Years of Age With Generalized Myasthenia Gravis(ADAPT Jr SC) | recruiting | Phase 2 / Phase 3 | 12 | argenxINDUSTRY | 14 | Sep 28, 2026 | clinicaltrials |
| NCT06514794 | A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex) | recruiting | Phase 2 | 125 | Allotera TherapeuticsINDUSTRY | 2 | Sep 28, 2026 | clinicaltrials |
| NCT06697184 | A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers. | recruiting | Phase 1 / Phase 2 | 258 | BeOne MedicinesINDUSTRY | 6 | Sep 28, 2026 | clinicaltrials |
| NCT06833073 | A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011) | recruiting | Phase 2 | 308 | Merck Sharp & Dohme LLCINDUSTRY | 19 | Sep 28, 2026 | clinicaltrials |
| NCT06961006 | A Clinical Study of Intismeran Autogene (V940) and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/INTerpath-012) | recruiting | Phase 2 | 160 | Merck Sharp & Dohme LLCINDUSTRY | 12 | Sep 28, 2026 | clinicaltrials |
| NCT07226999 | Symbiotic-Lung-04: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Extensive-Stage Small Cell Lung Cancer | recruiting | Phase 2 / Phase 3 | 550 | PfizerINDUSTRY | 10 | Sep 28, 2026 | clinicaltrials |
| NCT07421700 | Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer | recruiting | Phase 1 / Phase 2 | 132 | PfizerINDUSTRY | 6 | Sep 28, 2026 | clinicaltrials |
| NCT07843940 | A Study to Test Obrixtamig in Combination With Pumitamig in People With Advanced Small Cell Lung Cancer (Dareon®-Rosetta35) | not yet recruiting | Phase 1 / Phase 2 | 55 | Boehringer IngelheimINDUSTRY | 10 | Sep 28, 2026 | clinicaltrials |
| NCT03564340 | Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers | recruiting | Phase 1 / Phase 2 | 890 | Regeneron PharmaceuticalsINDUSTRY | 10 | Sep 25, 2026 | clinicaltrials |
| NCT04094610 | A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations | recruiting | Phase 1 / Phase 2 | 75 | Turning Point Therapeutics, Inc.INDUSTRY | 11 | Sep 25, 2026 | clinicaltrials |
| NCT04626479 | Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A) | completed | Phase 1 / Phase 2 | 393 | Merck Sharp & Dohme LLCINDUSTRY | 14 | Sep 25, 2026 | clinicaltrials |
| NCT04626518 | Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03) | completed | Phase 1 / Phase 2 | 263 | Merck Sharp & Dohme LLCINDUSTRY | 13 | Sep 25, 2026 | clinicaltrials |
| NCT04640623 | A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy(SunRISe-1) | active not recruiting | Phase 2 | 220 | Janssen Research & Development, LLCINDUSTRY | 16 | Sep 25, 2026 | clinicaltrials |
| NCT04811560 | A Phase 1/2 Study of Bleximenib in Participants With Acute Leukemia (cAMeLot-1)(cAMeLot-1) | recruiting | Phase 1 / Phase 2 | 420 | Janssen Research & Development, LLCINDUSTRY | 13 | Sep 25, 2026 | clinicaltrials |
| NCT04989803 | Study of KITE-363 or KITE-753 in Participants With Relapsed and/or Refractory B-cell Lymphoma(PALISADES-1) | recruiting | Phase 1 / Phase 2 | 247 | Kite, A Gilead CompanyINDUSTRY | 6 | Sep 25, 2026 | clinicaltrials |
| NCT05099003 | A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG) | recruiting | Phase 1 / Phase 2 | 132 | National Cancer Institute (NCI)NIH | 4 | Sep 25, 2026 | clinicaltrials |
| NCT05139017 | A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003) | recruiting | Phase 2 / Phase 3 | 290 | Merck Sharp & Dohme LLCINDUSTRY | 26 | Sep 25, 2026 | clinicaltrials |
| NCT05498155 | Study of Neoadjuvant Olaparib Monotherapy and Olaparib and Durvalumab Combination in HER2 Negative BRCAm Breast Cancer(OlympiaN) | completed | Phase 2 | 50 | AstraZenecaINDUSTRY | 9 | Sep 25, 2026 | clinicaltrials |
| NCT06172478 | A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors | recruiting | Phase 2 | 740 | Daiichi SankyoINDUSTRY | 16 | Sep 25, 2026 | clinicaltrials |
| NCT06428409 | A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A) | recruiting | Phase 1 / Phase 2 | 220 | Merck Sharp & Dohme LLCINDUSTRY | 13 | Sep 25, 2026 | clinicaltrials |
| NCT06550895 | A Study of Ciltacabtagene Autoleucel and Talquetamab for the Treatment of Participants With High-Risk Multiple Myeloma(MonumenTAL-8) | active not recruiting | Phase 2 | 11 | Janssen Research & Development, LLCINDUSTRY | 2 | Sep 25, 2026 | clinicaltrials |
| NCT06577025 | A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in Participants With Standard-risk Newly Diagnosed Multiple Myeloma(aMMbition) | active not recruiting | Phase 2 | 43 | Janssen Research & Development, LLCINDUSTRY | 5 | Sep 25, 2026 | clinicaltrials |
| NCT06667908 | A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)(CONVERGE) | recruiting | Phase 2 | 130 | Johnson & Johnson Enterprise Innovation Inc.INDUSTRY | 10 | Sep 25, 2026 | clinicaltrials |
| NCT06989437 | A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue | recruiting | Phase 2 / Phase 3 | 982 | PfizerINDUSTRY | 21 | Sep 25, 2026 | clinicaltrials |
| NCT07149857 | A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel(CARTITUDE-10) | recruiting | Phase 2 | 60 | Janssen Research & Development, LLCINDUSTRY | 3 | Sep 25, 2026 | clinicaltrials |
Data updated 7 hours agoSource updated unknownsource: clinicaltrials